Drugs Made In America Acquisition Corp. reported first-quarter 2026 results showing net income of $1.97M and diluted EPS of $0.06, both higher year over year as the company continues pre-merger activities and maintains funds in trust after its IPO.
Financial Highlights
- Net income: $1.97M for Q1 2026, up from $1.25M in Q1 2025 (57.2% YoY).
- Diluted earnings per share: $0.06 for Q1 2026, up from $0.05 in Q1 2025 (20.0% YoY).
Business Highlights
- Completed initial public offering and overallotment, raising $231.15M placed in trust to fund a business combination.
- Focused search on pharmaceutical targets and entered into a definitive merger agreement with PAGC to combine operations.
- Extended its combination deadline via shareholder vote; sponsor deposited funds to maintain the trust and extend the search period.
- No operating revenues to date; activities limited to IPO preparation, target identification, due diligence and transaction efforts.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.